New Zealand markets closed

Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I (INDP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.1300-0.0100 (-0.47%)
At close: 04:00PM EDT
2.0600 -0.07 (-3.29%)
After hours: 05:57PM EDT

Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I

Three Columbus Circle
15th Floor
New York, NY 10019
United States
646 427 2727

Full-time employees7

Key executives

NameTitlePayExercisedYear born
Mr. Jeffrey A. MecklerCEO & Director867.03kN/A1967
Dr. Michael J. Newman Ph.D.Founder, Chief Scientific Officer & Director659.99kN/A1956
Mr. Walt Addison Linscott Esq.Chief Operating Officer716.35kN/A1961
Mr. Nir SassiCFO, Secretary & Treasurer378.47kN/A1976
Dr. Roger J. Waltzman M.B.A., M.D.Chief Medical OfficerN/AN/A1968
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Corporate governance

Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.